自由容器
自由容器
您的位置:首页>新药研发
自由容器
Novel Degrader & PPl Discovery Platform
Proteasomal degradationduced by E3 ligase
Tripartite-designed Peptide degrader
● Cell-penetrating domain
● Binding domain
● Degron domain
Novel degradation modality unlock
newtherapeutic potential for degraders
PDR-001: Peptide-baseddegrader with a novel E3 ligand
Molecular Glue Discovery
● Al-driven Modeling & Virtual Screening
● High-throughput proteomics screening
● Noval target & E3 ligand identification
● Proximity-based assays validation
● In vivo validation & Translational medical
Small molecular candidates
自由容器-副本2
Non-degradative protein-protein interaction
Ternary Complex Optimization(DMPK)
FIND THE BEST DEGRADER
01
行业痛点
● 体内模型中降解 ≠ 药效，缺乏对致病蛋白的理解、降解与生物起效的量效关系和机制探索；
● CNS疾病缺乏基础研究和正确的评价模型，工业体系较肿瘤/自免等领域尚不健全
Biology
Evaluation
Target engagement -In vivo Efficacy- Potential Clinical Benefit
未来自研生物评价方向
●Neurodegenerative disease
● Neuropathic pain
● Neuroinflammation & autoimmune disorder